Mark Chan

Dr Mark Chan, MBBS, PhD, is an Adjunct Associate Professor at the Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore (NUS) and Senior Consultant at the Department of Cardiology, National University Heart Centre, Singapore.

He is deputy director of the Cardiovascular Disease Translational Research Program, NUS, and supervises translational research and clinical trials of acute myocardial infarction at the Cardiovascular Research Institute, NUS. He leads the post-myocardial infarction clinic at the National University Heart Centre, Singapore and the national Acute Myocardial Infarction: allied Health-Oriented, Patient-centred and technology-Enabled (AMI-HOPE) program with Singhealth and NHG colleagues. In 2019, he received the National Medical Research Council Clinician Scientist Senior Investigator Award.

He is overall PI of the 3-country randomized controlled trial of an anti-inflammatory small-molecule inhibitor to treat atherosclerosis in patients with AMI (PASSIvation of Vulnerable plaques with AZD5718 in acuTE coronary syndrome – the PASSIVATE trial) supported by a 10 million USD externally-sponsored from Astra-Zeneca.

Research Areas

Thrombosis and antithrombotic therapy, Biologics in cardiovascular drug discovery, Biomarker discovery in acute coronary syndrome, Outcomes and systems of care in acute coronary syndrome, Innovative clinical trials